This study will look at how well atorvastatin (a common cholesterol lowering agent) works with or without aspirin (a nonsteroidal anti-inflammatory drug) in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

The National Cancer Institute has opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, NBN, TP53, CHEK2, PALB2, RAD51C RAD51D, BRIP1, FANCA or ATM mutation. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.

This study looks at how well omega-3 fatty acid ethyl esters (generic Lovaza) work in preventing colorectal cancer in patients with Lynch syndrome. Omega-3 fatty acids work by decreasing inflammation, or swelling, in the body, and suppressing certain chemicals in the body that are known to cause cancer. The addition of omega-3 fatty acids to patients' diets may help decrease colon inflammation or suppress cancer-causing chemicals in the body.